Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiac Valve Surgery | Procedure: Acute Normovolemic Hemodilution | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 74 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Effect of Large Volume Acute Normovolemic Hemodilution on Perioperative Blood Transfusion and Outcomes in Cardiac Valve Surgery |
Actual Study Start Date : | May 27, 2019 |
Actual Primary Completion Date : | April 22, 2020 |
Actual Study Completion Date : | April 22, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Large Volume Acute Normovolemic Hemodilution
All the participants will undergo Large Volume Acute Normovolemic Hemodilution.
|
Procedure: Acute Normovolemic Hemodilution
Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight(Kg)×12-15(mL/Kg);Blood to be removed was capped at: Vmax=EVB×(Hi-Hf)/Hav(EBV= estimated blood volume (male:70mL/Kg,female:65mL/Kg);Hi= initial hemoglobin ;Hf=target Hb( 10g/dL );Hav= the average of the initial and minimal allowable hemoglobin).Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
(1)Low body weight (male: <50 kg;Female: < 45kg);(2)preoperative shock;(3)myocardial infarction within 3 months before surgery;(4)ischemic heart disease;Left main coronary artery stenosis >70%;Severe aortic stenosis (area < 0.7cm2);Severe changes in left ventricular function (ejection fraction <30%, requiring vasoactive agents to assist circulation);(5)uncontrolled hypertension;(6) severe carotid artery stenosis (>70% or with symptoms);(7) kidney failure (blood creatinine level >442 mmol/L) or dialysis treatment;(8) serum albumin level (ALB) is less than 25 g/L.(9) international standardized ratio (INR) >1.5 or platelet count <100 103/mm3;(10)Inherited/acquired coagulation function defect;(11)preoperative preparation platelet;(12) contagious or infectious diseases;(13) patient or family members refused to participate in research;(14)refused to infusion of autologous blood or allogeneic blood products
China, Zhejiang | |
The second affiliated hospital of Zhejiang University | |
Hangzhou, Zhejiang, China, 310000 |
Study Chair: | Min Yan, Doctor | Zhejiang University |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | April 24, 2019 | ||||
First Posted Date ICMJE | May 1, 2019 | ||||
Last Update Posted Date | May 12, 2020 | ||||
Actual Study Start Date ICMJE | May 27, 2019 | ||||
Actual Primary Completion Date | April 22, 2020 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Application of Large Volume Acute Normovolemic Hemodilution in Cardiac Valve Surgery | ||||
Official Title ICMJE | Effect of Large Volume Acute Normovolemic Hemodilution on Perioperative Blood Transfusion and Outcomes in Cardiac Valve Surgery | ||||
Brief Summary | The application of acute Normovolemic Hemodilution in cardiac surgery can effectively reduce perioperative blood transfusion, reduce postoperative complications and mortality, and is a low-cost, operable and effective blood protection measure.For the application of Acute Normovolemic Hemodilution in heart surgery, we still face an urgent problem: to what extent can Acute Normovolemic Hemodilution achieve better "blood saving effect", that is, whether a large number of Acute Normovolemic Hemodilution can reduce perioperative blood transfusion to a greater extent. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Prevention |
||||
Condition ICMJE | Cardiac Valve Surgery | ||||
Intervention ICMJE | Procedure: Acute Normovolemic Hemodilution
Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight(Kg)×12-15(mL/Kg);Blood to be removed was capped at: Vmax=EVB×(Hi-Hf)/Hav(EBV= estimated blood volume (male:70mL/Kg,female:65mL/Kg);Hi= initial hemoglobin ;Hf=target Hb( 10g/dL );Hav= the average of the initial and minimal allowable hemoglobin).Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
|
||||
Study Arms ICMJE | Experimental: Large Volume Acute Normovolemic Hemodilution
All the participants will undergo Large Volume Acute Normovolemic Hemodilution.
Intervention: Procedure: Acute Normovolemic Hemodilution
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE |
74 | ||||
Original Estimated Enrollment ICMJE |
72 | ||||
Actual Study Completion Date ICMJE | April 22, 2020 | ||||
Actual Primary Completion Date | April 22, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria: (1)Low body weight (male: <50 kg;Female: < 45kg);(2)preoperative shock;(3)myocardial infarction within 3 months before surgery;(4)ischemic heart disease;Left main coronary artery stenosis >70%;Severe aortic stenosis (area < 0.7cm2);Severe changes in left ventricular function (ejection fraction <30%, requiring vasoactive agents to assist circulation);(5)uncontrolled hypertension;(6) severe carotid artery stenosis (>70% or with symptoms);(7) kidney failure (blood creatinine level >442 mmol/L) or dialysis treatment;(8) serum albumin level (ALB) is less than 25 g/L.(9) international standardized ratio (INR) >1.5 or platelet count <100 103/mm3;(10)Inherited/acquired coagulation function defect;(11)preoperative preparation platelet;(12) contagious or infectious diseases;(13) patient or family members refused to participate in research;(14)refused to infusion of autologous blood or allogeneic blood products |
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | China | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03933917 | ||||
Other Study ID Numbers ICMJE | 2019-056 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Responsible Party | Second Affiliated Hospital, School of Medicine, Zhejiang University | ||||
Study Sponsor ICMJE | Second Affiliated Hospital, School of Medicine, Zhejiang University | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | Second Affiliated Hospital, School of Medicine, Zhejiang University | ||||
Verification Date | May 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |